Terra Innovatum Srl, a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. (NASDAQ:GSRT) announced accelerated progress in the U.S. Nuclear Regulatory Commission (NRC) licensing process for its SOLO™ reactor, marking key milestones in 2025 aimed at streamlining commercial deployment.
Since the start of the year, Terra Innovatum has submitted several critical regulatory documents and engaged in multiple meetings with NRC staff to expedite approvals. Key submissions currently under NRC review include:
- Commercial Fuel Use – Initiated discussions on using commercially available low enriched uranium (LEU) to simplify both supply chains and regulatory requirements.
- Environmental Report – Development underway for the first-of-a-kind deployment site.
- Principal Design Criteria (PDC) – Topical report submitted and accepted for review; completion of NRC review expected by the end of 2025.
- Factory Manufacturing, Transportation & Deployment White Paper – Outline submitted, with discussions ongoing with the NRC and U.S. Department of Transportation to secure permits for factory-based manufacturing and on-site assembly.
- Core Design Presentation – Innovative core design presented to NRC technical staff; dedicated review meeting scheduled for early October 2025.
- Emergency Planning Zone (EPZ) – Discussions initiated to limit the EPZ to the reactor operational boundary, reflecting SOLO’s inherent safety.
- Preliminary Safety Analysis Report (PSAR) Outline – Submitted with requests for justified exceptions to account for SOLO’s unique safety profile.
- Safeguards Methodology & Material Control & Accountancy (MC&A) – Detailed topical report submitted, describing implementation of material control verification and security technologies.
Cesare Frepoli, COO and Director of Regulatory Affairs, said: “Our team continues to focus on providing a robust set of technically detailed documents that validate the design, safety, and deployment planning of our SOLO reactor in order to accelerate our regulatory process. Each of these milestones underscores not just the accelerated pace at which we are advancing, but also the quality and depth of the information being submitted. We are encouraged by the strong and professional engagement with the NRC, and we remain confident in the path toward timely licensing and demonstration of the SOLO reactor with expected commercialization by 2028.”
Giordano Morichi, Partner and Chief Business Development Officer, added: “Our strategy from the beginning has been to design a close-to-completion solution that simplifies the regulatory process and is ready-made for commercial deployment. By leveraging commercially available LEU fuel, a factory-based deployment model, and our inherent safety design, we can streamline approvals and eliminate bottlenecks. For us, these regulatory milestones are not just technical achievements; they also propel us towards our commercialization timeline.”
Terra Innovatum expects continued progress throughout 2025, with NRC review of the SOLO PDC and topical reports targeted for completion by year-end, followed by PSAR submission in support of a 2026 construction permit application. Construction permit approval is anticipated by 2027, with commercialization expected by 2028.
About Terra Innovatum & SOLO™
Terra Innovatum is committed to making nuclear power accessible, delivering safe, scalable micro-reactor solutions deployable in 1 MWe increments. The SOLO™ Micro-Modular Reactor is engineered for rapid, cost-predictable deployment using commercial off-the-shelf components and adaptable to evolving fuel types, including LEU+ and HALEU.
SOLO™ provides versatile applications, supplying CO2-free, behind-the-meter, and off-grid power for data centers, mini-grids, and industrial operations in sectors such as cement, steel, oil & gas, and mining. It can also generate industrial heat and support specialized processes like water treatment, desalination, and co-generation. Its modular design allows scaling up to 1GW+ of zero-emission power, enabling rapid replacement of fossil fuel plants. Additionally, SOLO™ can produce medical radioisotopes critical for oncology research and cancer treatment.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.